During the past decade, Divisione di Ematologia - Istituto Nazionale dei Tumori conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 5 clinical trials were completed, i.e. on average, 17.9% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Divisione di Ematologia - Istituto Nazionale dei Tumori" #1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator and "ERIC Group" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Divisione di Ematologia - Istituto Nazionale dei Tumori" are "Chronic Lymphocytic Leukemia" (4 trials), "Hematologic Diseases" (3 trials), "Non-Hodgkin's Lymphoma" (3 trials), "Acute Myeloid Leukemia" (2 trials) and "Chronic Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Divisione di Ematologia - Istituto Nazionale dei Tumori" in a lesser frequency.

Most popular intervention types in "Divisione di Ematologia - Istituto Nazionale dei Tumori" are "Drug" (32 trials), "Other" (3 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (3 trials), "Tocilizumab" (3 trials), "Venetoclax" (3 trials), "Bendamustine" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Divisione di Ematologia - Istituto Nazionale dei Tumori" are 44 trials for "All" genders.

Currently, there are NaN active trials in "Divisione di Ematologia - Istituto Nazionale dei Tumori". undefined are not yet recruiting, 8 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Divisione di Ematologia - Istituto Nazionale dei Tumori, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Divisione di Ematologia - Istituto Nazionale dei Tumori, 5 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".